Presentation is loading. Please wait.

Presentation is loading. Please wait.

Residual Disease and Immune Activation/Inflammation on ART

Published byJunior Wheeler Modified over 6 years ago

Similar presentations

Presentation on theme: "Residual Disease and Immune Activation/Inflammation on ART"— Presentation transcript:

1 Residual Disease and Immune Activation/Inflammation on ART
IAS Meeting, Paris 2017 Monday 24 July, 14:30 – 17:00

2 Background The development of antiretroviral therapy (ART) for the treatment of HIV is one of the greatest achievements of modern medicine.

3 Improving Life Expectancy but Gap Persists
HIV- Controls HIV+ Well-treated: Implies HIV-infected individuals with CD4 cell count >350 cells per microliter and HIV RNA <500 copies per milliliter after 1 year of cART. Legarth/Obel, JAIDS, 2016 ~9y shorter life expectancy even among those with no comorbidity

4 Possible Reasons for “Unsuccessful Aging” among HIV+
ART Toxicity Unsuccessful Aging Genetics and Lifestyle Inflammation nadir predicts; jobs protect Adapted from Deeks and Phillips, BMJ, 2009

5 Immune Activation As a Tree
Leaves End-organ diseases Branches IL-6 D-dimer Lymphoid Fibrosis Roots HIV reservoirs CMV Microbial translocation Slide courtesy from Peter Hunt

6 THANK YOU!

Download ppt "Residual Disease and Immune Activation/Inflammation on ART"

Similar presentations

Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine,

Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine,
Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21): 2233-2244.

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.

Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.
Early Infant Diagnosis: Challenges and Solutions A special session IAS, Vienna 2010.

Early Infant Diagnosis: Challenges and Solutions A special session IAS, Vienna 2010.
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Suboptimal immune response among adults on first-line antiretroviral therapy within the IeDEA East Africa cohort Authors: Nakanjako D, Kiragga A, Yiannoutsos.

Suboptimal immune response among adults on first-line antiretroviral therapy within the IeDEA East Africa cohort Authors: Nakanjako D, Kiragga A, Yiannoutsos.
Controversies in HIV Cure Research 18.3 0 Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.

The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.

Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8): 607-614.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.

Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
The Basics. HIV infection is a lifelong condition that can be managed with the proper care and treatment. In this presentation, you will learn about:

The Basics. HIV infection is a lifelong condition that can be managed with the proper care and treatment. In this presentation, you will learn about:
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.

Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,

Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.

Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.

Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.

2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.

Similar presentations

Ads by Google